person

Donald C. Goff, MD

Donald C Goff, MDDonald GoffDonald Goff, MD
as of 2026-07-01
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
2 publications · 0 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Massachusetts General Hospital
Roles
Principal Investigator, Author
KOL signal
8
Publications
2 (0 high-value)
Trial investigator
yes

Publishes on

1 drugs

Trials led

13

Publications & congress

2
Reply to "Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia".
Journal of clinical psychopharmacology · 2025 Sep-Oct 01
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy).
Journal of clinical psychopharmacology · 2025 Mar-Apr 01

Facts & assertions

0 sourced
No assertions recorded for this entity.